KURA Stock Analysis: Buy, Sell, or Hold?
KURA - Kura Oncology, Inc.
$9.74
0.26 (2.74%)
▲
5d:
+4.51%
30d:
+7.62%
90d:
+21.45%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When KURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called KURA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KURA is currently trading at $9.74, which is considered extended relative to its 30-day fair value range of $8.81 to $9.54.
Technical Outlook: Technically, KURA is in a uptrend. The price is approaching resistance at $9.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KURA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.17 (+220.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KURA is in a uptrend. The price is approaching resistance at $9.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KURA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.17 (+220.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.81 -
$9.54
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 220.0% below Wall St target ($31.17)
Trading Range Analysis
30-Day Trading Range
$8.81 -
$9.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.67
Resistance Level
$9.95
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.89
Wall Street Target
$31.17
(+220.0%)
Revenue Growth (YoY)
29.5%
Share & Embed Analysis
Last updated: May 15, 2026 8:08 AM ET
Data refreshes hourly during market hours. Next update: 9:08 AM
Data refreshes hourly during market hours. Next update: 9:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Francis Burrows
SELL
1311 shares
2026-01-27
Kathleen Ford
SELL
1813 shares
2026-01-27
Mollie Leoni
SELL
8180 shares
2026-01-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 63 BUY |
